Clinical trials: Osteoporosis Postmenopausal
Osteoporosis
A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)
This study will assess the safety, tolerability, PK, and PD of a once weekly dose of MK0822 in healthy postmenopausal women.
- Trial name
- NCT00770159
- Testing
- odanacatib
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Low Bone Mineral Density
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD.
- Trial name
- NCT00043186
- Testing
- Denosumab, Alendronate
- Volunteers
- 412 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal, Type 2 Diabetes
Use of Ibandronate in Diabetic Patients
The purpose of this study is to examine whether monthly oral administration of ibandronate to postmenopausal osteoporosis patients with type 2 diabetes differs in safety and efficacy compared to patients without diabetes.
- Trial name
- NCT05266261
- Testing
- Ibandronate Oral Tablet
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Yeouido St. Mary's Hospital
Osteosarcopenia, Sarcopenia
The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women
Osteosarcopenia (OSP) is defined as the coexistence of sarcopenia and osteoporosis/osteopenia. There is an intense and complex interaction-both mechanical (the "mechanostat" hypothesis) and biochemical (involving factors such as…
- Conditions
- Osteosarcopenia, Sarcopenia, Postmenopausal Osteoporosis, Kinesiophobia
- Trial name
- Osteosarcopeni (NCT07910201)
- Testing
- Dual-energy x-ray absorptiometer
- Where
- Turkey (Türkiye)
- Volunteers
- 109 people
- Sponsor
- Ayşe Ukbe Baykut
Postmenopause, Osteoporosis
PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
The objectives of the study are to describe the quality of life at the beginning of the Preotact® treatment and at the end of the observational period (Qualeffo-41 questionnaire) pain assessment at the beginning of the Preotact®…
- Trial name
- NCT00515593
- Testing
- Parathyroid hormone (PTH) (Preotact)
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Nycomed
Osteoporosis
Safety and Effectiveness of Soy Phytoestrogens to Prevent Bone Loss
The purpose of this study is to determine whether soy isoflavone supplementation is safe and effective to prevent bone loss in postmenopausal women.
- Trial name
- OPUS (NCT00665860)
- Testing
- Soy isoflavones
- Where
- 3 sites in United States
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Breast Cancer, Osteoporosis
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help measure bone loss in women receiving treatment for breast cancer. The test results may help doctors plan better treatment.
- Trial name
- NCT00369850
- Testing
- laboratory biomarker analysis, Dual energy X-ray absorptiometry (DEXA), Spine X-ray
- Where
- 16 sites in Australia, France and 6 more
- Volunteers
- 458 people
- Sponsor
- ETOP IBCSG Partners Foundation
Osteoporosis, Postmenopausal
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
The purpose of this trial is to study: Effects of arzoxifene on bone fractures and bone mass. Effects of arzoxifene on getting breast cancer.
- Trial name
- NCT00088010
- Testing
- Arzoxifene
- Where
- United States
- Volunteers
- 9,369 people
- Sponsor
- Eli Lilly and Company
Post-menopausal Osteoporosis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.
- Trial name
- NCT01224717
- Testing
- PTH134, Forsteo
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 104 people
- Sponsor
- Novartis
Postmenopausal Women With Osteoporosis at High Risk of Fracture
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.
- Trial name
- NCT07062978
- Testing
- QL1206, Prolia®
- Where
- China
- Volunteers
- 278 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Osteoporosis, Osteopenia
Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women
Fruits and vegetables are rich in a variety of flavonoids with antioxidant properties. These compounds may be partially responsible for some of the positive links found between fruits and vegetables intake and higher bone mineral…
- Trial name
- NCT00330096
- Testing
- Hesperidin
- Where
- France
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Postmenopausal Osteoporosis, Postmenopausal Osteopenia
High Intensity Multi-Modal Exercise Training in Postmenopausal Women
in Pakistan 9.9 million people are osteoporotic and 7.2 million amongst them are women. Globally after every 3 seconds there is occurrence of fragility fracture.In Pakistan females carries different risk factors based on distinct…
- Trial name
- HIT-MMEX (NCT04653350)
- Testing
- High Intensity Exercises, General Exercises
- Where
- 2 sites in Pakistan
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Osteoporosis
A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women.
- Trial name
- NCT00540878
- Testing
- SB-751689 oral tablets (400 mg)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis, Osteopenia
Melatonin-Micronutrients for Osteopenia Treatment Study
The investigators' long-term goal is to employ novel methods to improve bone formation and bone density in women (and men) with osteopenia or osteoporosis while also decreasing signs and symptoms of degenerative joint and disc…
- Trial name
- MOTS (NCT01870115)
- Testing
- Fiber Pill, Melatonin, Strontium citrate, Vitamins D3 and K2
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Duquesne University
Osteoporosis
Insomnia in Postmenopausal Osteoporosis
Aim of the study was to determine the presence of sleep problems in postmenopausal osteoporosis patients and to examine the relationship between the severity of insomnia and mood and fatigue.
- Trial name
- NCT06646549
- Testing
- No intervention
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Beylikduzu State Hospital
Bone Loss, Post Menopausal Osteoporosis
Lactobacillus Acidophilus and Postmenopausal Women
This study aims to evaluate the effect of Lactobacillus acidophilus supplementation on calcium status and bone densitometry in postmenopausal women in a randomized, double-blind placebo-controlled study.
- Conditions
- Bone Loss, Post Menopausal Osteoporosis, Mineralization
- Trial name
- LaBon (NCT05332626)
- Testing
- Probiotic group
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- Poznan University of Life Sciences
Postmenopausal Osteoporosis, Spinal Fractures
Epidemiology, Identification Rate and Treatment Penetration of Osteoporotic Vertebral Fractures in Switzerland
In Switzerland, the prevalence of vertebral fractures in community- dwelling women is unknown and the published data from the Swiss hospitals statistics represent only the tip of the iceberg.
- Trial name
- SwOF (NCT02234414)
- Where
- 3 sites in Switzerland
- Volunteers
- 303 people
- Sponsor
- Prof. Dr. med. Kurt Lippuner
Osteoporosis, Postmenopausal Osteoporosis
Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility.
- Conditions
- Osteoporosis, Postmenopausal Osteoporosis, Frailty, Fragility Fractures
- Trial name
- LUMINOS (NCT07677072)
- Where
- Turkey (Türkiye)
- Volunteers
- 98 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Osteoporosis Fracture
Height Loss, Kyphosis Indicators, Bone Mineral Density and Vertebral Fractures in Chinese Postmenopausal Women
This is an observational and cross-sectional study on the height loss, kyphosis indicators, bone mineral density and vertebral fractures in Chinese postmenopausal women
- Trial name
- NCT03798444
- Testing
- dual energy X-ray absorptiometry, lateral spine imaging from T4 to L4 on X-ray
- Where
- China
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Central South University
Osteoporosis, Postmenopausal
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab
- Trial name
- EURODEC (NCT05575167)
- Testing
- Zoledronate or Alendronate
- Where
- 9 sites in France, Greece and 1 more
- Volunteers
- 122 people
- Sponsor
- 424 General Military Hospital